Walgreens Boots Alliance, Inc. (WBA) - NASDAQ
  • Thu, Jan. 14, 2:51 AM
    • WebMD (NASDAQ:WBMD), the U.S. online health information publisher, is exploring the possible sale of all or part of its business, FT reports.
    • The company is said to be in talks with Walgreens Boots Alliance (NASDAQ:WBA) and UnitedHealth (NYSE:UNH), among other potential buyers.
    • Since the start of the year WebMD shares have risen 10%, giving the company a market value of close to $2B.
    • Update: Shares are up 6% premarket on increased volume.
    | Thu, Jan. 14, 2:51 AM
  • Thu, Jan. 7, 7:52 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) reports comparable-store sales rose 5.8% in FQ1.
    • Retail pharmacy USA division sales rose 4.2% to $20.37B.
    • Pharmacy sales rose 6.7% on a 4.7% gain in prescription count for the quarter.
    • Adjusted gross margin rate fell 130 bps to 26%.
    • Adjusted gross margin rates by segment: Retail Pharmacy USA 27%, Retail Pharmacy International 42.6%, Pharmaceutical Worldwide 9.6%.
    • Adjusted SG&A expense rate -210 bps to 20.1%.
    • Adjusted operating margin rate increased 20 bps to 5.9%.
    • FY2016 Guidance: Adjusted EPS: $4.30 to $4.55.
    • WBA -0.19% premarket.
    | Thu, Jan. 7, 7:52 AM
  • Dec. 15, 2015, 9:00 AM
    • Valeant Pharmaceuticals (NYSE:VRX) enters into a 20-year fulfillment agreement with Walgreens (NASDAQ:WBA) under which consumers can conveniently access Valeant's dermatology and ophthalmology products and its over-the-counter portfolio from more than 8,000 Walgreens U.S.-based pharmacies. In addition, it will reduce the wholesale list prices of its branded prescription-based dermatology and ophthalmology offerings by 10%, to be phased in over the next six to nine months. The agreement takes effect in Q1.
    • The companies have also inked a separate deal under which Valeant will distribute more than 30 branded products, where generics are available, through Walgreens at generic prices. The discounted pricing, ranging from 5% to 95%, will be available to patients in H2 2016. Eligible products represent dermatology, ophthalmology, gastrointestinal and neurology/other and include Aldara, Tiazac and Glumetza.
    • Valeant expects the price discounts to provide up to $600M in annual savings to the U.S. healthcare system, when fully implemented.
    • The company intends to extend this distribution model to additional independent retail pharmacies.
    | Dec. 15, 2015, 9:00 AM | 48 Comments
  • Oct. 28, 2015, 10:43 AM
    • Execs with Walgreen Boots Alliance (NASDAQ:WBA) said the EnvisionRX business it will swallow up as part of the Rite Aid purchase will help it learn how to increase PBM synergies. EnvisionRX was acquired by Rite Aid earlier this year for $2B.
    • A very interesting question on how many stores will be divested or closed as part of the Rite Aid deal goes unanswered. Walgreens will have strategic and regulatory reasons to make some store changes.
    • What about tobacco? As Walgreens pushed deeper into pharmacy benefits and healthcare services the sale of tobacco appears to be a stickler. For now, Walgreens has no update.
    • Management also talked about some positive trends in the front end of its stores.
    • Investors are in a selling mood this morning on WBA, shares are down 8.4% on heavy volume. It's possible the EPS impact of pulling the buyback program could be factoring in.
    • Previously: Walgreens Boots beats by $0.07, beats on revenue (Oct. 28 2015)
    • Previously: Synergies start to kick in for Walgreens Boots Alliance (Oct. 28 2015)
    • Walgreens Boots Alliance earnings call webcast
    | Oct. 28, 2015, 10:43 AM | 16 Comments
  • Oct. 28, 2015, 7:45 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) reports total sales in comparable drugstores rose 6.4% in FQ4 off a 1.5% retail comp.
    • Pharmacy sales grew 8.2% on a 4.6% gain in prescription count for the quarter.
    • Adjusted gross margin rates (non-GAAP) by segment: Retail Pharmacy USA 26.3%, Retail Pharmacy International 42.6%, Pharmaceutical Worldwide 9.4%.
    • Total drugstore count -34 Y/Y to 8,173.
    • Combined synergy benefits for the full fiscal year came in at $799M.
    • Guidance: The company expects FY16 EPS of $4.25 to $4.55. The outlook reflects the suspension of the share repurchase program in order to finance the Rite Aid acquisition.
    • Previously: Walgreens Boots beats by $0.07, beats on revenue (Oct. 28 2015)
    • WBA +0.57% premarket to $95.70.
    | Oct. 28, 2015, 7:45 AM
  • Oct. 27, 2015, 5:27 PM
    • Confirming media reports, Walgreens Boots (NASDAQ:WBA) announces it's buying fellow drugstore owner Rite Aid (NYSE:RAD) for $17.2B after factoring debt, or $9/share, in cash. The deal is expected to close in 2H16; Walgreen expects to eventually reap over $1B/year in synergies.
    • The price represents a 48% premium to Rite Aid's Monday close, and is also $0.33 above Rite Aid's Tuesday close of $8.67. Nonetheless, Rite Aid is down 6.3% after hours to $8.12, as a healthy M&A arb spread opens. Walgreens is up 0.9% to $96.00, after rising 6.4% in regular trading.
    • Following the deal's closing, Rite Aid is expected to initially continue operating under its existing brand. However, decisions "will be made over time regarding the integration of the two companies, ultimately creating a fully harmonized portfolio of stores and infrastructure."
    • Walgreens plans to finance the deal with both debt and existing cash. It's expected to be accretive in its first year after closing.
    | Oct. 27, 2015, 5:27 PM | 90 Comments
  • Oct. 27, 2015, 12:45 PM
    • Rite Aid (NYSE:RAD) shares have reopened for trading with a 39.7% burst on a Dow Jones report that Walgreens Boots Alliance (NASDAQ:WBA) is close to a deal to acquire the firm.
    • The deal -- which would link the No. 2 and No. 3 drugstore chains in the U.S. -- is expected to come tomorrow, sources tell Dow Jones.
    • Typical takeover premiums could value Rite Aid at close to $10B in the purchase, vs. its pre-news $6B market cap.
    • In its last quarter, Rite Aid’s profit sank due to cost of integrating recently acquired Envision Pharmaceutical Services, the WSJ notes.
    • Updated 12:55 p.m.: Walgreens shares have spiked on the news as well, up 4.3%.
    • Related: Riding The Rite Aid Roller Coaster (Oct. 27 2015)
    | Oct. 27, 2015, 12:45 PM | 44 Comments
  • Jul. 9, 2015, 7:28 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) reports comparable-store sales rose 1.6% in FQ3.
    • Pharmacy sales grew 7% on a 3.8% gain in prescription count for the quarter.
    • Gross profit margin rate decreased 206 bps to 26%.
    • Adjsuted SG&A expense rate -240 bps to 20.1%.
    • Adjusted operating margin rate fell 22 bps to 6.07%.
    • Total drugstores count +8 Q/Q to 8,240.
    • FY2015 Guidance: Adjusted EPS: $3.70 to $3.80.
    • FY2016 Guidance: Adjusted EPS: $4.25 to $4.60.
    • WBA +2.72% premarket.
    | Jul. 9, 2015, 7:28 AM | 1 Comment
  • Apr. 9, 2015, 7:30 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) reports comparable-store sales rose 2.5% in FQ2.
    • Pharmacy sales were up 10.1% on a  4.8% gain in prescription count for the quarter.
    • Gross profit margin -292 bps to 25.90%.
    • SG&A expenses +22.70% to $5.606B.
    • Adjusted operating margin rate declined 26 bps to 6.92%.
    • FY2015 Guidance: Adjusted EPS: $3.45 to $3.65; Ineterest expense: $140M to $150M; Tax rate: ~29%.
    • FY2016 Guidance: Adjusted EPS: $4.25 to $4.60.
    • WBA +1.15% premarket.
    | Apr. 9, 2015, 7:30 AM | 2 Comments
  • Jan. 6, 2015, 8:38 AM
    • Walgreens Boots Alliance (NASDAQ:WBA) announces December sales rose 10.2% to $7.92 for the Walgreen brand.
    • Front-end sales +3.5% Y/Y on a +2.6% comp.
    • Comp traffic rose 0.3%, while the average basket size was 2.3% higher.
    • Flu shots season-to-date +13.4% to 7.6M.
    • WBA +2.2% premarket.
    | Jan. 6, 2015, 8:38 AM
  • Dec. 23, 2014, 7:38 AM
    • Walgreen (NYSE:WAG) reports comparable-store sales rose 1.5% in FQ1.
    • Traffic at stores was down 2.7% on a comp basis, while the average basket size improved 4.2%.
    • Pharmacy sales were up 9% on a 4.3% gain in prescription count for the quarter.
    • Gross profit margin -100 bps to 27.1%.
    • SG&A expenses +1.8% to $4.456B.
    • WAG +2.3% premarket.
    | Dec. 23, 2014, 7:38 AM
  • Dec. 23, 2014, 7:34 AM
    • Walgreen (NYSE:WAG): FQ1 EPS of $0.81 beats by $0.06.
    • Revenue of $19.55B (+6.7% Y/Y) beats by $50M.
    • Shares +2.33% PM.
    | Dec. 23, 2014, 7:34 AM | 2 Comments
  • Sep. 30, 2014, 7:54 AM
    • Walgreen (NYSE:WAG): FQ4 EPS of $0.74 in-line.
    • Revenue of $19.1B (+6.5% Y/Y) beats by $80M.
    • Shares +2% PM.
    | Sep. 30, 2014, 7:54 AM
  • Sep. 22, 2014, 8:37 AM
    • Walgreen (NYSE:WAG) is downgraded by Barclays to an Equal-weight rating from Overweight on a reduced view of the company's ability to meet its EPS guidance.
    • WAG -0.9% premarket
    | Sep. 22, 2014, 8:37 AM
  • Sep. 18, 2014, 9:30 AM
    • Shares of Walgreen (NYSE:WAG) and CVS Caremark (NYSE:CVS) are showing some weakness early after results from Rite Aid (NYSE:RAD) take a hit from generic drug introductions.
    • Walgreen is down 0.4% premarket, while CVS is tilting 0.6% south.
    • Rite Aid (RAD) is in a dive, now down 13.4%.
    | Sep. 18, 2014, 9:30 AM | 1 Comment
  • Sep. 5, 2014, 10:11 AM
    • Unconfirmed chatter Carl Icahn has a stake in Walgreen (WAG +1.9%) has the stock popping higher in mid-morning action.
    | Sep. 5, 2014, 10:11 AM | 7 Comments
Company Description
Walgreens Boots Alliance, Inc. provides drug store services. It operates through the following segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment engages in pharmacy-led health and beauty retail businesses, which sells its... More
Sector: Services
Industry: Drug Stores
Country: United States